Mortality Outcome of Controlled Hypertension

NCT07187596 | Active Not Recruiting

• 1 other identifier: NathaphongDejthida
• Study Type: observational
• Target: 2,547
• Locations: 1 country
• Sites: 1

Brief Summary

This pooled analysis investigates death outcomes in patients with pharmacologically treated and blood pressure-controlled hypertension. Despite documented BP control, some patients still suffer fatal cardiovascular, cerebrovascular, renal, or unexplained syndromes. This study aims to synthesize available evidence across study types to identify treatment pitfalls, contributing syndromes, and non-BP factors associated with these fatal outcomes. February 14th, 2026. Total search hits: 9,297 articles from your hypertension-mortality PubMed strategy Working dataset: 2,547 unique records. Screened so far: 50 (2.0%). Mostly excluded because: Not the right treatment strategy. No mortality outcome. Less often: wrong population.

Conditions

Arterial Aneurysm; Arterial Rupture; Hypertension; Morality; Death; Pre-Eclampsia; Cardiovascular Diseases; Stroke; Renal Disease; Artery Stenosis; Maternal Death

Keywords

Controlled blood pressure; Mortality outcomes

Outcome Measures

Primary Outcomes (1)

• All-cause vascular mortality

  Cardiovascular mortality (Cardiac-related death in controlled hypertension patients), cerebrovascular death(Stroke-related fatal outcomes in BP-controlled patients), renal occlusion/rupture/failure causing death (Mortality from renal failure in treated, controlled hypertensives), life-threatening vascular rupture, Major Adverse Cardiovascular Death or

  Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years

Secondary Outcomes (5)

• Sudden death

  Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 10 years

• End-organ failure leading to death

  90 days outcomes after participant recruitment (death/alive)

• ICU death

  90 days outcomes start with day 1 admit at ICU (death/alive)

• Maternal associated hypertension death

  During pregnancy period from GA 1 week to delivery (pre-term, term-post-term) to 6 week follow up postpartum

• Hypertension associated death in the young

  Day one until last follow up at least 24 hour to study completion date at least 30 days outcomes but not over 18 years of ages of participant

Eligibility Criteria

• Age: 1 Minute - 130 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Studies including patients (any age or sex) with: * Interventional treatment for hypertension * Documented blood pressure control (as defined by each primary study) * Reported mortality or fatal outcome

You may qualify if:

• Human studies (RCTs, cohort, case-control, registry studies, etc.) declare participants with treated and controlled hypertension manage (regardless of drug class, duration, or comorbidity) reported mortality outcomes: all-vascular death, cardiovascular death, sudden death, etc.
• Studies in any setting (outpatient, inpatient, long-term follow-up)
• Articles in English
• Full-text available

You may not qualify if:

• Animal specimen or parameter studies
• Uncontrolled studies (e.g., case series without control, phase I safety trials)
• No mortality endpoint reported
• Purely mechanistic studies or trials that do not address BP or survival directly
• Pediatric studies unless separated subgroup for treated hypertension is available
• Glaucoma or portal hypertension or Pulmonary Hypertension without essential/systemic hypertension outcomes
• Infection without direct declare that septic shock or immunological failure associated by vascular cause from systemic hypertension
• Secondary/post-hoc analyses that do not report original mortality data

Sponsors & Collaborators

• DejthidaNathaphong: lead

Study Sites (1)

Owned study

Bangkok, 10110, Thailand

Location

Related Links

• PROSPERO registry

MeSH Terms

Conditions

Hypertension; Death; Pre-Eclampsia; Cardiovascular Diseases; Stroke; Kidney Diseases; Maternal Death

Condition Hierarchy (Ancestors)

Vascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Hypertension, Pregnancy-Induced; Pregnancy Complications; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Urologic Diseases; Female Urogenital Diseases; Male Urogenital Diseases; Parental Death

Study Officials

• Nathaphong Dejthida, MD

  DejthidaNathaphong

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principle Investigator

Study Record Dates

• First Submitted: September 9, 2025
• First Posted: September 23, 2025
• Study Start: September 18, 2025
• Primary Completion (Estimated): December 18, 2026
• Study Completion (Estimated): December 14, 2027
• Last Updated: April 13, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will share
• Shared Documents: STUDY PROTOCOL, SAP, CSR, ANALYTIC CODE
• Time Frame: TIMELINE OF THE REVIEW Date of first submission to PROSPERO 01 July 2025 Review timeline Start date: 14 June 2025. End date: 31 December 2025. Date of registration in PROSPERO 01 July 2025
• Access Criteria: Public registered

Locations

TH (1)